The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended PBS listings for several treatments for patients with haematological cancers and haemoglobinuria. At its July meeting the PBAC recommended the listing of acalabrutinib (Calquence) for people with relapsed and/or refractory mantle cell lymphoma (R/R MCL) who have received at least one prior therapy and have a WHO ...
New PBS listings recommended for acalabrutinib, elotuzumab and ravulizumab
By Michael Woodhead
26 Aug 2021